Zurcher Kantonalbank Zurich Cantonalbank Has $406,000 Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 15.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 76,730 shares of the company’s stock after purchasing an additional 10,272 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Recursion Pharmaceuticals were worth $406,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of RXRX. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares during the last quarter. NewEdge Advisors LLC lifted its position in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after acquiring an additional 2,387 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $54,000. San Luis Wealth Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter worth approximately $54,000. Finally, ADG Wealth Management Group LLC bought a new position in shares of Recursion Pharmaceuticals during the first quarter worth approximately $55,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Down 1.3%

RXRX opened at $5.41 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 4.11. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The firm has a market capitalization of $2.20 billion, a PE ratio of -3.04 and a beta of 0.93. The company’s 50-day moving average is $5.38 and its 200 day moving average is $5.92.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%. The firm had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $7.00.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.